Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda

Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda

* Organic revenue growth(1) of 5% with growth in all operating segments * Operating income(2) grew by 23%, resulting in further margin expansion to 11.7% * Reported operating income grew by 10% and reported net income(3) decreased by 3% * Earnings per share(2) (EPS) increased by 28%, supported by the share buyback program * 227 U.S. clinics converted to the 5008X CAREsystem with more than 600,000 treatments(4) * Reaffirms FY 2026 outlook BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered another quarter of highly profitable growth, driven by solid organic revenue growth and improved profitability," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Care Delivery achieved strong operating income(2) growth. Importantly, underlying operating income(2) improved by 34% excluding the positive TDAPA effects, driven by rate improvements and benefits from revenue cycle management. The U.S. rollout of our innovative 5008X CAREsystem is progressing at speed, now available in 227 U.S. clinics, having performed more than 600,000 treatments. We are excited by the benefits we are seeing through early insights from our scientific research initiative BEACON-US and the potential for this therapy to significantly improve patient outcomes in the U.S.," Giza continued, "Operating income growth in the first half was in line with our planned phasing for the full year and we confirm our outlook for 2026. Through disciplined execution of the FME Reignite strategy, we are further improving the quality of patient care, investing in innovation and profitable future growth, addressing regulatory headwinds – creating long-term value for our shareholders."